S&P 500   5,253.05 (+0.09%)
DOW   39,778.57 (+0.05%)
QQQ   444.26 (-0.13%)
AAPL   171.75 (-0.90%)
MSFT   420.59 (-0.20%)
META   487.76 (-1.24%)
GOOGL   150.99 (+0.08%)
AMZN   180.23 (+0.22%)
TSLA   176.83 (-1.67%)
NVDA   904.20 (+0.19%)
NIO   4.52 (-3.21%)
AMD   180.34 (+0.42%)
BABA   72.47 (+1.23%)
T   17.65 (+0.57%)
F   13.22 (+1.23%)
MU   117.82 (-1.11%)
CGC   8.60 (-9.95%)
GE   175.08 (-2.80%)
DIS   122.45 (+1.22%)
AMC   3.67 (-15.44%)
PFE   27.93 (+0.54%)
PYPL   67.09 (+0.78%)
XOM   116.14 (+1.02%)
S&P 500   5,253.05 (+0.09%)
DOW   39,778.57 (+0.05%)
QQQ   444.26 (-0.13%)
AAPL   171.75 (-0.90%)
MSFT   420.59 (-0.20%)
META   487.76 (-1.24%)
GOOGL   150.99 (+0.08%)
AMZN   180.23 (+0.22%)
TSLA   176.83 (-1.67%)
NVDA   904.20 (+0.19%)
NIO   4.52 (-3.21%)
AMD   180.34 (+0.42%)
BABA   72.47 (+1.23%)
T   17.65 (+0.57%)
F   13.22 (+1.23%)
MU   117.82 (-1.11%)
CGC   8.60 (-9.95%)
GE   175.08 (-2.80%)
DIS   122.45 (+1.22%)
AMC   3.67 (-15.44%)
PFE   27.93 (+0.54%)
PYPL   67.09 (+0.78%)
XOM   116.14 (+1.02%)
S&P 500   5,253.05 (+0.09%)
DOW   39,778.57 (+0.05%)
QQQ   444.26 (-0.13%)
AAPL   171.75 (-0.90%)
MSFT   420.59 (-0.20%)
META   487.76 (-1.24%)
GOOGL   150.99 (+0.08%)
AMZN   180.23 (+0.22%)
TSLA   176.83 (-1.67%)
NVDA   904.20 (+0.19%)
NIO   4.52 (-3.21%)
AMD   180.34 (+0.42%)
BABA   72.47 (+1.23%)
T   17.65 (+0.57%)
F   13.22 (+1.23%)
MU   117.82 (-1.11%)
CGC   8.60 (-9.95%)
GE   175.08 (-2.80%)
DIS   122.45 (+1.22%)
AMC   3.67 (-15.44%)
PFE   27.93 (+0.54%)
PYPL   67.09 (+0.78%)
XOM   116.14 (+1.02%)
S&P 500   5,253.05 (+0.09%)
DOW   39,778.57 (+0.05%)
QQQ   444.26 (-0.13%)
AAPL   171.75 (-0.90%)
MSFT   420.59 (-0.20%)
META   487.76 (-1.24%)
GOOGL   150.99 (+0.08%)
AMZN   180.23 (+0.22%)
TSLA   176.83 (-1.67%)
NVDA   904.20 (+0.19%)
NIO   4.52 (-3.21%)
AMD   180.34 (+0.42%)
BABA   72.47 (+1.23%)
T   17.65 (+0.57%)
F   13.22 (+1.23%)
MU   117.82 (-1.11%)
CGC   8.60 (-9.95%)
GE   175.08 (-2.80%)
DIS   122.45 (+1.22%)
AMC   3.67 (-15.44%)
PFE   27.93 (+0.54%)
PYPL   67.09 (+0.78%)
XOM   116.14 (+1.02%)
NASDAQ:MNKD

MannKind (MNKD) Stock Price, News & Analysis

$4.55
-0.08 (-1.73%)
(As of 02:34 PM ET)
Today's Range
$4.49
$4.74
50-Day Range
$3.25
$5.27
52-Week Range
$3.17
$5.75
Volume
1.09 million shs
Average Volume
3.18 million shs
Market Capitalization
$1.23 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00

MannKind MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
75.1% Upside
$8.00 Price Target
Short Interest
Bearish
13.22% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.40mentions of MannKind in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
77.78%
From $0.09 to $0.16 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.07 out of 5 stars

Medical Sector

661st out of 939 stocks

Pharmaceutical Preparations Industry

305th out of 433 stocks

MNKD stock logo

About MannKind Stock (NASDAQ:MNKD)

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

MNKD Stock Price History

MNKD Stock News Headlines

MannKind Announces CFO Transition
Jim Cramer Says You Should Avoid These 11 Stocks
AI Bubble Now at Critical Mass
Washington, D.C., has just issued its first round of new artificial-intelligence (“AI”) regulations. And a flood of additional AI bills is making its way through Congress. Nasdaq reports this could bring a screeching halt to the AI stock boom.
MannKind (NASDAQ:MNKD) Stock Price Up 3.6%
MNKD Mar 2024 5.000 put
MNKD Mar 2024 4.000 call
MNKD Mar 2024 4.500 put
Warning: this could blow your mind
Buckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…
What's Going On With MannKind Stock?
MNKD Mar 2024 6.500 call
MNKD Mar 2024 3.000 put
MNKD Mar 2024 3.500 put
MNKD Mar 2024 7.000 call
MannKind Full Year 2023 Earnings: Beats Expectations
Q4 2023 MannKind Corp Earnings Call
MannKind Stock (NASDAQ:MNKD) Insider Trades
See More Headlines
Receive MNKD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MannKind and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/27/2024
Today
3/28/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:MNKD
CUSIP
56400P20
Employees
411
Year Founded
1991

Price Target and Rating

Average Stock Price Target
$8.00
High Stock Price Target
$10.00
Low Stock Price Target
$6.50
Potential Upside/Downside
+70.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-11,940,000.00
Pretax Margin
-5.22%

Debt

Sales & Book Value

Annual Sales
$198.96 million
Book Value
($0.91) per share

Miscellaneous

Free Float
259,601,000
Market Cap
$1.27 billion
Optionable
Optionable
Beta
1.27

Social Links

Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Michael E. Castagna Pharm.D. (Age 47)
    CEO & Director
    Comp: $1.26M
  • Mr. Steven B. BinderMr. Steven B. Binder (Age 61)
    Chief Financial Officer
    Comp: $800.2k
  • Dr. David B. Thomson J.D. (Age 57)
    Ph.D., Executive VP, General Counsel & Secretary
    Comp: $798.53k
  • Dr. Stuart A. Tross Ph.D. (Age 57)
    Executive VP and Chief People & Workplace Officer
    Comp: $678.4k
  • Mr. Sanjay Singh M.B.A. (Age 58)
    Executive Vice President of Technical Operations
    Comp: $364.53k
  • Ms. Lauren M. Sabella (Age 63)
    Executive VP & COO
  • Ms. Rosabel Realica Alinaya (Age 63)
    VP of Investor Relations & Treasury
    Comp: $402.26k
  • Mr. John F. Bedard (Age 74)
    Senior Vice President of Worldwide Regulatory Affairs
  • Mr. James Patrick McCauley Jr. (Age 58)
    J.D., M.B.A., Chief Commercial Officer
    Comp: $614.06k
  • Dr. Matthew H. Nguyen PharmD (Age 54)
    Senior Vice President of Endocrine Business Unit

MNKD Stock Analysis - Frequently Asked Questions

Should I buy or sell MannKind stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MannKind in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MNKD shares.
View MNKD analyst ratings
or view top-rated stocks.

What is MannKind's stock price target for 2024?

3 Wall Street research analysts have issued 1 year target prices for MannKind's shares. Their MNKD share price targets range from $6.50 to $10.00. On average, they anticipate the company's stock price to reach $8.00 in the next twelve months. This suggests a possible upside of 75.1% from the stock's current price.
View analysts price targets for MNKD
or view top-rated stocks among Wall Street analysts.

How have MNKD shares performed in 2024?

MannKind's stock was trading at $3.64 at the start of the year. Since then, MNKD shares have increased by 25.5% and is now trading at $4.57.
View the best growth stocks for 2024 here
.

When is MannKind's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our MNKD earnings forecast
.

How were MannKind's earnings last quarter?

MannKind Co. (NASDAQ:MNKD) announced its quarterly earnings data on Tuesday, February, 27th. The biopharmaceutical company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.01) by $0.02. The biopharmaceutical company had revenue of $58.47 million for the quarter, compared to analysts' expectations of $52.36 million.

What ETFs hold MannKind's stock?

ETFs with the largest weight of MannKind (NASDAQ:MNKD) stock in their portfolio include Invesco Biotechnology & Genome ETF (PBE) and ALPS Medical Breakthroughs ETF (SBIO).iShares Micro-Cap ETF (IWC).

What other stocks do shareholders of MannKind own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MannKind investors own include Bausch Health Companies (BHC), Novavax (NVAX), Geron (GERN), ACADIA Pharmaceuticals (ACAD), Advanced Micro Devices (AMD), Chesapeake Energy (CHKAQ), Micron Technology (MU), NVIDIA (NVDA), Intel (INTC) and Gilead Sciences (GILD).

Who are MannKind's major shareholders?

MannKind's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (5.66%), Vanguard Group Inc. (5.64%), Nitorum Capital L.P. (4.02%), Goldman Sachs Group Inc. (1.13%), Goldman Sachs Group Inc. (1.13%) and Northern Trust Corp (0.98%). Insiders that own company stock include Alejandro Galindo, Anthony C Hooper, David Thomson, Michael Castagna, Steven B Binder, Stuart A Tross and Stuart A Tross.
View institutional ownership trends
.

How do I buy shares of MannKind?

Shares of MNKD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MNKD) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners